icatibant: Clinical Trials

28 trials of icatibant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 2 active not recruiting, 2 terminated, 1 withdrawn. 11 Phase 3, 9 Phase 2, 4 Phase 4, 2 Not applicable, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 311Completed 10, Active not recruiting 1
Phase 29Completed 7, Active not recruiting 1, Withdrawn 1
Phase 44Completed 3, Terminated 1
Not applicable2Completed 2
Phase 12Completed 1, Terminated 1

Follow icatibant: new trials by email Literature Review of icatibant trials Research Report on icatibant

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
Icatibant Injection (Icanticure®) - Bradykinin-mediated Angioedema, Hereditary Angioedema (HAE)
Phase 4CompletedNang Kuang Pharmaceutical Co., Ltd.52024-09-272025-12-18
Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
Icatibant, Placebo - Intradialytic Hypotension
Phase 3Active not recruitingVanderbilt University Medical Center262023-12-112026-10-22
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Icatibant - Hereditary Angioedema (HAE)
CompletedTakeda322022-08-242026-08-07
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection
Phase 2 / Phase 3CompletedBelfast Health and Social Care Trust322022-05-162023-09-07
Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection
Firazyr, SoC - COVID-19 Pneumonia
Phase 2CompletedSebastian Videla732021-04-122022-08-03
Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).
C1 Inhibitor Human, Icatibant Injection, Placebo - Covid19
Phase 2CompletedGCS Ramsay Santé pour l'Enseignement et la Recherche442021-02-042022-12-22
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
TAK-667 - Hereditary Angioedema
Phase 3CompletedTakeda22021-01-152022-03-29
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Remdesivir, Imatinib Mesylate, Dexamethasone - COVID-19
Phase 2Active not recruitingQuantumLeap Healthcare Collaborative15002020-07-312026-03-16
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
LCZ 696, Icatibant, placebo - Heart Failure
Phase 4CompletedVanderbilt University Medical Center462019-11-012026-08-11
FIRAZYR General Drug Use-Results Survey (Japan)
Firazyr - Hereditary Angioedema (HAE)
CompletedShire1792018-11-202025-02-21
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid - Heart Failure NYHA Class I, Heart Failure NYHA Class II
Phase 2WithdrawnVanderbilt University Medical Center2017-09-012018-01-11
Mitochondria and Chronic Kidney Disease
Icatibant, Placebo - Hemodialysis-Induced Symptom, Mitochondrial Diseases
Phase 2CompletedVanderbilt University Medical Center112017-08-012019-10-29
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
Icatibant - Hereditary Angioedema (HAE)
Phase 3CompletedShire82015-03-182021-06-03
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
Icatibant (30 mg) - Hereditary Angioedema (HAE)
Phase 1CompletedShire122014-02-212021-06-03
Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Icatibant, Placebo - Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Phase 3CompletedShire1182013-12-022021-06-08
A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema
icatibant - Hereditary Angioedema (HAE)
Phase 3CompletedShire322012-01-272021-06-08
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
Icatibant - Hereditary Angioedema
Phase 4CompletedMassachusetts General Hospital192011-12-012016-10-18
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema
icatibant, Placebo - ACE Inhibitor-associated Angioedema
Phase 4TerminatedVanderbilt University Medical Center332011-08-012017-02-17
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
Icatibant - Hereditary Angioedema
Phase 3CompletedShire1512009-09-252021-06-11
The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway
Forearm vascular study, Placebo, bradykinin receptor antagonist (HOE-140) - Ischaemic Heart Diseases
Not applicableCompletedUniversity of Edinburgh122009-08-012010-10-25

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Angioedemas, Hereditary (12)  ·  Angioedema (5)  ·  COVID-19 (3)  ·  Coronary Artery Disease (2)  ·  Cardiovascular Diseases (1)  ·  Disease (1)  ·  Genetic Diseases, Inborn (1)  ·  Heart Failure (1)  ·  Hypersensitivity (1)  ·  Hypersensitivity, Immediate (1)  ·  Immune System Diseases (1)  ·  Inflammation (1)  ·  Joint Diseases (1)  ·  Mitochondrial Diseases (1)  ·  Osteoarthritis (1)

Sponsors

Shire (9)  ·  Vanderbilt University Medical Center (5)  ·  Takeda (2)  ·  University of Edinburgh (2)  ·  Vanderbilt University (2)  ·  Belfast Health and Social Care Trust (1)  ·  GCS Ramsay Santé pour l'Enseignement et la Recherche (1)  ·  Massachusetts General Hospital (1)  ·  Nang Kuang Pharmaceutical Co., Ltd. (1)  ·  QuantumLeap Healthcare Collaborative (1)  ·  Sanofi (1)  ·  Sebastian Videla (1)  ·  Technical University of Munich (1)

Countries

United States (15)  ·  United Kingdom (5)  ·  Germany (4)  ·  Israel (4)  ·  Japan (4)  ·  Austria (3)  ·  Canada (3)  ·  Italy (3)  ·  Spain (3)  ·  Australia (2)  ·  France (2)  ·  Hungary (2)  ·  Argentina (1)  ·  Colombia (1)  ·  Czechia (1)

Top investigators

David E Newby, PhD, FRCP (2)  ·  Nancy J. Brown, MD (2)  ·  Rajesh K Kharbanda, PhD, FRCP (2)  ·  Aleena Banerji, M.D. (1)  ·  Derek W Russell, MD (1)  ·  Joe Kidney, MD (1)  ·  Jorge L Gamboa, MD/PhD (1)  ·  Kathleen D Liu, MD (1)  ·  Laura Esserman, MD (1)  ·  Mias Pretorius, MBChB (1)  ·  Murat Bas, Dr. (1)  ·  Nancy J. Brown, M.D. (1)

Results publications

PMID 20818888, PMID 21873443, PMID 17073887, PMID 22123383, PMID 23167682, PMID 23361105, PMID 24111645, PMID 24438203, PMID 24749847, PMID 25198193, PMID 25629740, PMID 26556097, PMID 28552382, PMID 28601641, PMID 34473343, PMID 35413921, PMID 36610464, PMID 36883141, PMID 38035747, PMID 39592213, PMID 40462830, PMID 42028604, PMID 42630033, PMID 42799508

NIH funding

2004 (1), 2008 (1), 2009 (1), 2014 (1), R01HL079184 (1)